CHMP backs Krka's generic of Jakavi across three indications; EC decision now pending
The 12 November positive opinion for Ruxolitinib Krka covers myelofibrosis, polycythaemia vera and graft-versus-host disease. What is settled, what is not, and what teams should check.
What happened
On 12 November 2026 the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Ruxolitinib Krka, a generic of Jakavi. The medicine is proposed for myelofibrosis, polycythaemia vera and graft-versus-host disease. The opinion now goes to the European Commission, which issues the legally binding marketing authorisation decision.
A CHMP opinion is a recommendation, not an authorisation. Until the Commission decides, Ruxolitinib Krka cannot be marketed in the EU under this authorisation. In general terms, the Commission normally adopts its decision within about two months of an opinion, though the records do not give a date for this one.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources this analysis is based on
- CHMP backs Krka's generic ruxolitinib for myelofibrosis, polycythaemia vera and graft-versus-host disease EMA · Fri 13 Nov 2026
- Imricor starts US launch of NorthStar iMR system after paediatric FDA clearances Imricor Medical Systems, Inc. · Fri 13 Nov 2026
- FDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy Intellia Therapeutics, Inc. · Fri 13 Nov 2026
- FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100 Neonc Technologies Holdings, Inc. · Fri 13 Nov 2026
- Cingulate nearly done with manufacturing fixes for ADHD drug CTx-1301 ahead of NDA resubmission Cingulate Inc. · Fri 13 Nov 2026
- CHMP backs Cosentyx for adolescents aged 12+ with moderate-to-severe hidradenitis suppurativa Novartis Pharma AG · Fri 13 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
FTC's bid to block Covetrus-MWI puts veterinary distribution, and PV information flow, in focus
The US suit against a $3.5bn merger of the two largest vet distributors is an antitrust case, but animal-health PV teams should check how safety information moves through the channel.
Vercise DBS instruction recall: why IFU corrections matter to trial teams
Health Canada's Type II recall of Vercise clinician programmer instructions is narrow, but it shows how a labelling correction can ripple into protocols, training and site files.
Denmark's Voltabak shortage to mid-May 2027 shows how fragile single-source supply is
DKMA's updated notice on Laboratoires Thea's diclofenac eye drops, with the Methergin withdrawal and estradiol patch notices, shows how Denmark manages supply failures.